灯盏花素治疗急性脑梗死47例临床观察

Clinical observation on the therapy of acute cerebral infarction with breviscapine in 47 cases

目的:观察灯盏花素治疗急性脑梗死(ACI)的临床效果和安全性。方法:将95例ACI患者随机分为治疗组47例和对照组48例,分别给予灯盏花素和血塞通注射液静脉滴注治疗。结果:治疗组治疗前后的神经功能缺损程度评分有高度显著性差异(P<0.001);治疗组的显效率为66.0%,对照组的显效率为50.0%,两者比较无显著性差异(P>0.05);但治疗组的总有效率为87.2%,显著优于对照组的68.8%(P<0.05),且未见明显不良反应。结论:灯盏花素是治疗ACI安全、有效的药物之一。

Objective： To investigate the effect and safety of breviscapine in the treatment of acute cerebral infarction（ACI）. Methods： Ninety-five patients with ACI were divided randomly into study group（ n = 47） and control group（ n =48）, and were treated with breviscapine and xuesaitong through intravenous injection respectively , the results were analyzed. Results： There were significant differences in nerve functional defect scale before and after treatment in the study group （ P 〈 0.001 ）. The effectual rate in the two groups has no significant difference （66.0% vs 50.0% ,P 〉 0.05）. The total effective rate in study group was significantly higher than that in control group （87.2% vs 68.8%,P 〈 0.05）. There were slight side effects. Conclusion： Breviscapine is one of the drugs that can treat ACI effectively and safely.